Isolation and structural identification of an impurity in fluconazole bulk drug substance

Journal of Pharmaceutical and Biomedical Analysis

Volumn 45, Issue 3, 2007, Pages 422-429

  Dongre, Vaijanath G ^a   Ghugare, Pradeep D ^a,b   Karmuse, Pravin P ^a,b   Soudagar, Satish R ^b   Panda, Nalinakshya ^b   Kumar, Ashok ^b  

^a UNIVERSITY OF MUMBAI   (India)

^b Ipca Laboratories Ltd   (India)

Author keywords

Fluconazole; Identification; Impurities; IR; Isolation; NMR; Semi preparative HPLC

Indexed keywords

2 (2 (DIMETHYLAMINO) 4 FLUOROPHENYL) 1,3 DI(3H 1,2,4 TRIAZOL 1 YL)PROPAN 2 OL; FLUCONAZOLE; PROPANOL; UNCLASSIFIED DRUG;

ARTICLE; DRUG IMPURITY; DRUG ISOLATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; FLUCONAZOLE; MOLECULAR STRUCTURE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 35349010074     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2007.06.029     Document Type: Article

References (20)

1. Grant S.M., and Clissold S.P. Drugs 39 (1990) 877-916
2. Morrow J.D. Am. J. Med. Sci. 302 (1991) 129-132
3. Kunze K.L., Wienkers L.C., Thummel K.E., and Trager W.F. Drug Metab. Dispos. 24 (1996) 414-421
4. In: Rossi S. (Ed). Australian Medicines Handbook 2006 (2006), Australian Medicines Handbook, Adelaide. 0-9757919-2-3
5. Braunwald E. Harrison's Principle of Internal Medicine. 15th ed. (2003), McGraw-Hill p. 1170
6. United state Pharmacopeia, Pharmacopeial Forum 31 (2005) 408-410.
7. Chinese Pharmacopeia 2 (2000) 290.
8. European Pharmacopoeia, Pharmacopeial Forum 16 (2004) 441-442.
9. Creaser C.S., Stygall J.W., Bower D.V., and Pullen F.S. Talanta 44 (1997) 1025-1035
10. Cyr T.D., Dawson B.A., Neville G.A., and Shurvell H.F. J. Pharm. Biomed. Anal. 14 (1996) 247-255
11. Sun S., Lou H., Gao Y., Fan P., Ma B., Ge W., and Wang X. J. Pharm. Biomed. Anal. 34 (2004) 1117-1124
12. Eerkes A., Shou W.Z., and Naidong W. J. Pharm. Biomed. Anal. 31 (2003) 917-928
13. ICH guideline, Impurities in new drug substances Q3A (R), dated February 7, 2002.
14. K. Myeong, Y. Jung, European Patent Application KR19990013635 19990416 (2000).
15. Clive et al., Patent 5,872,258 (1998).
16. Narayanan A., Chapman D.R., Upadhyaya S.P., and Bauer L. J. Heterocycl. Chem. 30 (1993) 1405-1412
17. Dongre V., Karmuse P., Ghugare P., Salunke S., Panda N., and Kumar A. J. Pharm. Biomed. Anal. 42 (2006) 334-340
18. Indian Patent Application, 12/MUM/2005 (2005).
19. Silverstein R.M., and Webster F.X. Spectrometric Identification of Organic Compounds. 6th ed. (1996), Wiley, New York pp. 8-9
20. Eliel E.L., and Wilen S.H. Stereochemistry of Organic Compounds (1994), Wiley Interscience Publication pp. 572-573